Product Information
LAYOLIS FE CHEWABLE TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $1.6438 per EA under NDC 52544006431. Its NADAC has been published 556 times since Aug 12, 2015.
FDA first approved this application on Dec 22, 2010.
Manufacturer
Actavis Pharma, Inc.NDC
52544006431
Classification
Generic
Dosage Form
KIT
Route
ORAL
Effective Date
3/18/2026
Approval Type
Authorized Generic (NDA)
FDA Application
NDA022573FDA Approved
12/22/2010
On Market Since
12/23/2011
Price Statistics
The NADAC for LAYOLIS FE CHEWABLE TABLET has been published 556 times since Aug 12, 2015, and over the history we have for it it has declined 58.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.6438 per EA |
|---|---|
| All-time high | $4.3997 (Jan 11, 2017) |
| All-time low | $0.9745 (Feb 21, 2024) |
| 52-week high | $1.8790 |
| 52-week low | $1.6438 |
| Median price | $2.1350 |
| Average price | $2.2963 |
| Largest weekly change | +54.1% (Sep 22, 2021) |
| Weeks tracked | 556 |
| Tracking since | Aug 12, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
-12.5%
3Y
+6.0%
5Y
-39.0%
All
-58.1%
Last surveyed Apr 1, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the norethindrone, ethinyl estradiol, and ferrous fumarate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norethindrone, ethinyl estradiol, and ferrous fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAYOLIS FE CHEWABLE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAYOLIS FE CHEWABLE TABLET, manufactured by Actavis Pharma, Inc., is $1.6438 per EA (NDC 52544006431), effective Apr 1, 2026.
How has the price of LAYOLIS FE CHEWABLE TABLET changed over time?
Over the history we have for it, the NADAC for LAYOLIS FE CHEWABLE TABLET has declined 58.1%. It has been tracked across 556 weekly CMS publications since Aug 12, 2015.
What are the highest and lowest recorded NADAC prices for LAYOLIS FE CHEWABLE TABLET?
Since Aug 12, 2015, the NADAC for LAYOLIS FE CHEWABLE TABLET has ranged from a low of $0.9745 (Feb 21, 2024) to a high of $4.3997 (Jan 11, 2017), with a median of $2.1350 per EA.
Are there cheaper alternatives to LAYOLIS FE CHEWABLE TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LAYOLIS FE CHEWABLE TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LAYOLIS FE CHEWABLE TABLET?
LAYOLIS FE CHEWABLE TABLET (NDC 52544006431) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.